Factors and HCV treatment outcomes associated with smoking among people who inject drugs on opioid agonist treatment: secondary analysis of the PREVAIL randomized clinical trial.

ABSTRACT:

Background

Cigarette smoking has emerged as a leading cause of mortality among people with hepatitis C virus (HCV). People who inject drugs (PWID) represent the largest group of adults infected with HCV in the US. However, cigarette smoking remains virtually unexplored among this population. This study aimed at (1) determining prevalence and correlates of cigarette smoking among HCV-infected PWID enrolled in opiate agonist treatment programs; (2) exploring the association of smoking with HCV treatment outcomes including adherence, treatment completion and sustained virologic response (SVR); and 3) exploring whether cigarette smoking decreased after HCV treatment.

Methods

Participants were 150 HCV-infected PWID enrolled in a randomized clinical trial primarily designed to tes

SUBMITTER: Pericot-Valverde I 

PROVIDER: S-EPMC7718688 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature